Business Context and Reporting Period
This Form 8-K is a current report filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on October 15, 2015. The filing serves to disclose an investor presentation delivered at the Dawson James Investor Conference on the same date. The company is incorporated in Delaware and operates in the wound care and medical device sectors.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a conduit for an attached presentation (Exhibit 99.1) rather than a financial statement itself. Consequently, no quantitative financial metrics can be extracted from this specific text.
Material Changes
No material changes to financial position or operations are detailed within the text of this filing. The primary event reported is the dissemination of forward-looking information and strategic updates via the investor presentation.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the company's future activities, including:
- Expectations for profitability and the timing of development programs.
- Regulatory approvals from the FDA and other agencies.
- Progress of clinical trials and physician studies.
- Strategic partnerships and market penetration strategies.
- Intellectual property protection and litigation outcomes.
Risks and Contingencies: Management explicitly states that actual results may differ materially from forecasts due to numerous uncertainties. Key risks include the ability to become profitable, regulatory hurdles, manufacturing capabilities, and the concentration of revenue from international sales. The company disclaims any obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the actual financial figures and strategic details contained in Exhibit 99.1 (the Management Presentation), as they are not included in the 8-K text.
- Confirm the company name is Oculus Innovative Sciences, Inc. (the input metadata referenced Sonoma Pharmaceuticals, which is incorrect for this filing).
- Review the most recent Form 10-K for detailed risk factors and historical financial performance referenced in the forward-looking statement disclaimer.
- Monitor FDA communication timelines and clinical trial progress as highlighted in the risk factors.